AMPE - Ampio Pharmaceuticals, Inc.

NYSE American - NYSE American Delayed Price. Currency in USD
2.93
+0.01 (+0.34%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close2.92
Open2.94
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.86 - 3.03
52 Week Range0.38 - 4.95
Volume1,020,243
Avg. Volume1,843,354
Market Cap222.509M
Beta1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.20
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est14.00
Trade prices are not sourced from all markets
  • What Does Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Ownership Structure Look Like?
    Simply Wall St.13 hours ago

    What Does Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Ownership Structure Look Like?

    In this analysis, my focus will be on developing a perspective on Ampio Pharmaceuticals Inc’s (AMEX:AMPE) latest ownership structure, a less discussed, but important factor. The impact of a company’sRead More...

  • PR Newswire8 days ago

    Ampio Presentation at J.P. Morgan Healthcare Conference made available to all Shareholders

    ENGLEWOOD, Colo. , Jan. 8, 2018 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces that the company will be updating potential collaborators and attending shareholders at the J.P. Morgan ...

  • Did Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Recent Earnings Growth Beat The Trend?
    Simply Wall St.12 days ago

    Did Ampio Pharmaceuticals Inc’s (NYSEMKT:AMPE) Recent Earnings Growth Beat The Trend?

    Examining how Ampio Pharmaceuticals Inc (AMEX:AMPE) is performing as a company requires looking at more than just a years’ earnings. Below, I will run you through a simple sense checkRead More...

  • Here's Why Ampio Pharmaceuticals Sank as Much as 13.5% Today
    Motley Fool12 days ago

    Here's Why Ampio Pharmaceuticals Sank as Much as 13.5% Today

    An important industry analyst has little hope for the tiny company.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool17 days ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    2017 ended with a bang for these biotech stocks. But can their momentum continue into the new year?

  • Why Ampio Pharmaceuticals Rose as Much as 15% Today
    Motley Fool19 days ago

    Why Ampio Pharmaceuticals Rose as Much as 15% Today

    The small-cap biopharma stock has exploded at the end of 2017.

  • SmarterAnalystlast month

    Ampio Pharmaceuticals Inc (AMPE) Rallies as Knee Osteoarthritis Drug Findings Cheer

    Case in point: Ampio Pharmaceuticals Inc (NYSE:AMPE), whose shares are jumping nearly 50% in Thursday trading session. The biopharmaceutical company reported that its knee osteoarthritis drug Ampion met its primary endpoint in Phase 3 clinical trial. Specifically, 71% of Ampion treated patients met OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee.

  • Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)
    PR Newswirelast month

    Ampio Pharmaceuticals Reports Positive Results for both Primary and Secondary Endpoints of Pivotal Phase 3 Trial of Ampion™ in Severe Osteoarthritis-of-the Knee (OAK)

    ENGLEWOOD, Colo., Dec. 14, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today reported that the Phase 3 clinical trial of Ampion™ met its primary endpoint with 71% of Ampion™ treated patients meeting the OMERACT-OARSI responder criteria, which exceeds the physician reported threshold of 30% for a meaningful treatment in severe osteoarthritis of the knee (p

  • ACCESSWIRElast month

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Versartis

    NEW YORK, NY / ACCESSWIRE / December 4, 2017 / It was an exciting day for biotech companies Ampio Pharmaceuticals and Versartis. Both stocks had big closes in the green. Ampio has engaged with LaVoieHealthScience ...

  • PR Newswire2 months ago

    Ampio Pharmaceuticals Announces Engagement of LaVoieHealthScience for Integrated Public and Investor Relations

    ENGLEWOOD, Colo., Nov. 30,  2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the engagement of LaVoieHealthScience for their services in investor and public relations. LaVoieHealthScience, an integrated investor and public relations agency focused on advancing health and science innovations, will be supporting Ampio in their strategic communications with a broad range of audiences including media, healthcare professionals, the investment community and others.  LaVoieHealthScience will use their 16 years of proven industry tactics to help Ampio extend visibility and optimize value.

  • ACCESSWIRE2 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Agenus Inc.

    NEW YORK, NY / ACCESSWIRE / November 24, 2017 / Shares of Ampio blew up on Wednesday after encouraging data was published in a peer review journal about its Ampion serum that is being developed to treat ...

  • PR Newswire2 months ago

    Ampio Announces Publication of Ampion™ Treatment of Severe Osteoarthritis of the Knee as a Feature Article in Orthopedics Peer-Reviewed Journal

    The article describes the efficacy and safety of Ampion™ (LMWF-5A) in an integrated analysis of three single injection randomized controlled studies of severe osteoarthritis of the knee (Kellgren-Lawrence [KL] grade 4 disease).

  • PR Newswire2 months ago

    Ampio Pharmaceuticals, Inc. Announces Continued Listing Plan Accepted by NYSE American

    ENGLEWOOD, Colo., Nov. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio" or the "Company") today announced the receipt of notification that the Company's plan to regain compliance with the NYSE American's continued listing standards has been accepted by the NYSE American LLC ("NYSE American"). As previously reported by the Company in a Current Report on Form 8-K on September 7, 2017, the Company received a letter from the NYSE American on September 1, 2017 stating that the Company was not in compliance with the continued listing standards of the NYSE American Company Guide (the "Company Guide") relating to stockholders' equity.

  • PR Newswire2 months ago

    Ampio Announces Start of Open Label Extension Study to Support Commercial Label of Repeat Administration of Ampion™ in Severe Osteoarthritis of the Knee

    ENGLEWOOD, Colo., Nov. 15, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announced the beginning of an Open Label Extension (OLE) study of Ampion™ in patients with severe osteoarthritis of the knee (OAK). The OLE study offers patients an opportunity to receive repeat injections of Ampion™ after they have completed the pivotal clinical trial. Ampion™ is the low molecular weight fraction of pharmaceutical 5% human serum albumin (HSA).

  • PR Newswire3 months ago

    Ampio Pharmaceuticals, Inc. Announces Closing of Registered Direct Offering

    ENGLEWOOD, Colo., Oct. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE American: AMPE) ("Ampio") today announced that it has closed it's previously announced registered direct offering of 7,709,400 shares of common stock at a purchase price of $0.875 per share for gross proceeds of approximately $6.75 million. The sale of the common stock was offered by Ampio pursuant to a shelf registration statement on Form S-3 (Registration No. 333-217094), which was declared effective by the Securities and Exchange Commission (the "SEC") on April 20, 2017. A final prospectus supplement was filed with the SEC and forms a part of the effective registration statement.

  • PR Newswire3 months ago

    Ampio Pharmaceuticals, Inc. Announces Pricing of Registered Direct Offering

    ENGLEWOOD, Colo., Oct. 16, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has entered into a securities purchase agreement with investors providing for the registered sale of approximately $6.75 million of shares of common stock at a purchase price of $0.875 per share. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes, including funding of the Ampion™ clinical trial. Joseph Gunnar & Co., LLC, and Fordham Financial Management, Inc. are acting as placement agents for the offering.

  • ACCESSWIRE3 months ago

    Today’s Research Reports on Stocks to Watch: Ampio Pharmaceuticals and Ardelyx Inc.

    NEW YORK, NY / ACCESSWIRE / October 13, 2017 / Shares of both Ampio Pharmaceuticals (NYSE American: AMPE ) and Ardelyx Inc. (NASDAQ: ARDX ) soared on Thursday after both companies had data news, respectively. ...

  • PR Newswire3 months ago

    Ampio Announces Accepted Publication of Pooled Ampion™ Clinical Trial Results in Patients with Severe Osteoarthritis of the Knee

    ENGLEWOOD, Colo., Oct. 12, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that a manuscript titled: "LMWF-5A For The Treatment Of Severe Osteoarthritis Of The Knee: Integrated Analysis Of Safety And Efficacy" was accepted for publication in Orthopedics, an international peer-reviewed journal in the field of Orthopedics. Ampion™ is the Low Molecular Weight Fraction of 5% human serum Albumin (LMWF-5A). Ampio's Chief Scientific Officer, Dr. David Bar-Or described the study as follows: "This was a combined analysis of all completed single-injection Ampion™ randomized placebo-controlled trials to date, focusing on the subset of patients with severe (Kellgren-Lawrence [KL] grade 4) osteoarthritis of the knee (OAK).

  • PR Newswire4 months ago

    Ampio Completes Enrollment of Patients in 12-Week Pivotal Trial

    ENGLEWOOD, Colo., Sept. 18, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) announces the completion of enrollment and dosing of patients in their pivotal single injection study on the "unmet medical need" of severe osteoarthritis of the knee (OAK).  These patients experience not only pain but also the loss of function and diminished quality of life. The primary endpoint of this pivotal trial follows the Osteoarthritis Research Society International (OARSI) guidance, utilizing the Outcome Measures in Rheumatology Clinical Trials (OMERACT) OMERACT-OARSI responder rate to address the signs and symptoms of severe OAK. Michael Macaluso, Ampio's CEO, noted, "Announcing the close of enrollment so quickly speaks to the unmet medical need.

  • PR Newswire4 months ago

    Ampio Pharmaceuticals, Inc. Announces Annual Shareholder Meeting

    ENGLEWOOD, Colo. , Sept. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...

  • PR Newswire4 months ago

    Ampio Pharmaceuticals, Inc. to Present at the 19th Annual Rodman & Renshaw Global Investment Conference

    ENGLEWOOD, Colo. , Sept. 7, 2017 /PRNewswire/ --   Ampio Pharmaceuticals, Inc. (NYSE: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies to treat prevalent ...

  • PR Newswire4 months ago

    Ampio Discloses Receipt of Notice from NYSE American and Has Until March 1, 2019, to Gain Compliance

    ENGLEWOOD, Colo., Sept. 7, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE: American: AMPE) ("Ampio" or the "Company") announces that on September 1, 2017, it was notified by the NYSE American (the "Exchange") that the Company was not in compliance with certain of the Exchange's continued listing standards as set forth in Part 10 of the NYSE American Company Guide (the "Company Guide"). To maintain its listing on the Exchange, the Exchange has requested that the Company submit a plan of compliance (the "Plan") by October 2, 2017, addressing how it intends to regain compliance by March 1, 2019.

  • PR Newswire5 months ago

    Ampio Announces the Allowance of a Composition and Methods Patent in the USA Using Ampion™ in Conjunction with Stem Cells

    ENGLEWOOD, Colo., Aug. 8, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) is pleased to announce today the allowance of an important composition and methods patent in the USA complimenting a series of patents on Ampion™ (127 issued and 80 pending). The patent is entitled: "COMPOSITIONS FOR THE MOBILIZATION, HOMING, EXPANSION, AND DIFFERENTIATION OF STEM CELLS AND METHODS OF USING THE SAME."  The patent includes 34 allowed claims. Autologous or allogenic stem cells are used in clinical practice, including for osteoarthritis of the knee.

  • PR Newswire6 months ago

    Ampio Hosting Conference Call, Wednesday, July 12, 4:30 pm EDT

    ENGLEWOOD, Colo. , July 6, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT:  AMPE) hosting a conference call Wednesday, July 12th at 4:30 pm EDT . Participants are invited to dial in using the ...

  • PR Newswire7 months ago

    Ampio Injects First Patient in Final Pivotal Clinical Trial for Ampion™ BLA

    ENGLEWOOD, Colo., June 22, 2017 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) initiates dosing in the AP-003-C, Phase 3, single injection Ampion™ study.  This study addresses the "unmet medical need" in Kellgren-Lawrence (KL) grade 4 osteoarthritis of the knee (OAK), evaluating the efficacy of Ampion™ for the treatment of pain, function, and Patient Global Assessment (PGA) in severe OAK. The study's primary endpoint follows the Outcome Measures in Rheumatology Clinical Trials (OMERACT) and Osteoarthritis Research Society International (OARSI) guidance, utilizing the OMERACT-OARSI responder rate. Osteoarthritis (OA) is a progressive disorder of the joints involving degradation of the intra-articular cartilage, joint lining, ligaments, and bone.